Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
30-40% of patients who undergo radical prostatetecomy (RP) with curative intent for their
localized prostate cancer experience relapse of their disease. Thus, improved therapeutic
approaches are needed in this patient population. Enhancing the patient's anti-tumor immune
response prior to surgery may improve long-term outcomes following RP.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Lawrence Fong Washington University School of Medicine